Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study

Matsuda, Akira; Taniwaki, Masafumi; Jinnai, Itsuro; Harada, Hironori; Watanabe, Mitsumasa; Suzuki, Kenshi; Yanagita, Soshi; Suzuki, Takahiro; Yoshida, Yataro; Kimura, Akiro; Tsudo, Mitsuru; Tohyama, Kaoru; Takatoku, Masaaki; Ozawa, Keiya

doi:10.1016/j.leukres.2011.11.011

« Previous Next »Leukemia Research
Volume 36, Issue 5 , Pages 575-580, May 2012

Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study

Akira Matsuda
- Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan
- Corresponding author at: Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan. Tel.: +81 42 984 4674; fax: +81 42 984 4741.
Masafumi Taniwaki
- Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Itsuro Jinnai
- Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan
Hironori Harada
- Department of Hematology and Oncology, Hiroshima University, Hiroshima, Japan
Mitsumasa Watanabe
- Osaka Red Cross Hospital, Osaka, Japan
Kenshi Suzuki
- Japan Red Cross Medical Center, Tokyo, Japan
Soshi Yanagita
- Shizuoka General Hospital, Shizuoka, Japan
Takahiro Suzuki
- Division of Hematology, Jichi Medical University, Shimotsuke, Japan
Yataro Yoshida
- Takeda General Hospital, Kyoto, Japan
Akiro Kimura
- Department of Hematology and Oncology, Hiroshima University, Hiroshima, Japan
Mitsuru Tsudo
- Japan Red Cross Medical Center, Tokyo, Japan
Kaoru Tohyama
- Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan
Masaaki Takatoku
- Celgene Corporation K.K., Tokyo, Japan
Keiya Ozawa
- Division of Hematology, Jichi Medical University, Shimotsuke, Japan

Received 9 September 2011; received in revised form 19 November 2011; accepted 19 November 2011. published online 16 December 2011.

Abstract

Lenalidomide is known to be effective in myelodysplastic syndromes (MDS) with del(5q) in improving anemia and suppressing del(5q) cells. MDS with del(5q) shows increase of nonlobulated megakaryocytes. However, histopathology of MDS with del(5q) treated with lenalidomide has not been fully studied. We investigated the morphologic changes in lenalidomide treated low- or intermediate-1-risk MDS with del(5q). All of evaluable patients showed high proportion of nonlobulated megakaryocytes. The nonlobulated megakaryocytes were markedly decreased in 6 patients during therapy in parallel with suppression of del(5q) cells. Our analysis suggests that single allele deletion of common deleted region inhibits nuclear lobulation of megakaryocytes.

Keywords: Lenalidomide, Myelodysplastic syndromes, Chromosome 5q deletion, Dysplasia, Nonlobulated megakaryocytes, Mononuclear megakaryocytes